EA007632B1 - Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера - Google Patents

Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера Download PDF

Info

Publication number
EA007632B1
EA007632B1 EA200401617A EA200401617A EA007632B1 EA 007632 B1 EA007632 B1 EA 007632B1 EA 200401617 A EA200401617 A EA 200401617A EA 200401617 A EA200401617 A EA 200401617A EA 007632 B1 EA007632 B1 EA 007632B1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
alzheimer
treatment
antagonist
dementia
Prior art date
Application number
EA200401617A
Other languages
English (en)
Russian (ru)
Other versions
EA200401617A1 (ru
Inventor
Ларс Ликке Томсен
Андерс Герсел Педерсен
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA007632(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Priority claimed from PCT/DK2003/000342 external-priority patent/WO2003101458A1/en
Publication of EA200401617A1 publication Critical patent/EA200401617A1/ru
Publication of EA007632B1 publication Critical patent/EA007632B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA200401617A 2002-05-31 2003-05-22 Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера EA007632B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
PCT/DK2003/000342 WO2003101458A1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EA200401617A1 EA200401617A1 (ru) 2005-06-30
EA007632B1 true EA007632B1 (ru) 2006-12-29

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401617A EA007632B1 (ru) 2002-05-31 2003-05-22 Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера

Country Status (9)

Country Link
KR (1) KR101016927B1 (is)
CN (1) CN1655793A (is)
AR (1) AR040121A1 (is)
CA (1) CA2426492C (is)
EA (1) EA007632B1 (is)
IS (1) IS7558A (is)
PE (1) PE20040623A1 (is)
UA (1) UA82480C2 (is)
ZA (1) ZA200409147B (is)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014054965A1 (ru) 2012-10-01 2014-04-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинация для профилактики и лечения поведенческих, психических и когнитивных расстройств

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
WO2018062941A1 (ko) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR20210072569A (ko) 2019-12-09 2021-06-17 주식회사 종근당 도네페질 및 메만틴을 포함하는 복합 제제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Acetylcholinesterase Inhibitors vs. Memantine, Volume 66, No 12, 2000, Gary L. Wenk et al., "NO INTERACTION OF MEMANTINE WITH ACETYL CHOLINESTERASE INHIBITORS APPROVED FOR CLINICAL USE", page 1079-page 1083 *
International Clinical Psychopharmacology, Volume 18, No 2, 2003, Susanne Hartman et al., "Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy", page 81-page 85, 18 February 2003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014054965A1 (ru) 2012-10-01 2014-04-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинация для профилактики и лечения поведенческих, психических и когнитивных расстройств

Also Published As

Publication number Publication date
AR040121A1 (es) 2005-03-16
CA2426492A1 (en) 2003-09-16
UA82480C2 (uk) 2008-04-25
KR101016927B1 (ko) 2011-02-28
EA200401617A1 (ru) 2005-06-30
IS7558A (is) 2004-11-26
KR20050024296A (ko) 2005-03-10
PE20040623A1 (es) 2004-09-11
ZA200409147B (en) 2006-06-28
CN1655793A (zh) 2005-08-17
CA2426492C (en) 2006-10-03

Similar Documents

Publication Publication Date Title
AU2003227516B2 (en) A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU2005219439B2 (en) 1-aminocyclohexane derivatives for the treatment of agitation and other behavioural disorders, especially those associated with alzheimer's disease
AU2021209279B2 (en) Therapeutic uses of L-4-chlorokynurenine
US20110172251A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2008510700A (ja) 抗うつ薬と組み合わせてコレステロール低下剤を使用する心理的障害および認知障害の治療法
CN101257907A (zh) 左旋佐匹克隆和抗抑郁剂的组合
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
US20050119248A1 (en) Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JPS63243028A (ja) 基本的うつ病を軽減するためのうつ病治療剤
MXPA04005716A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo.
CN116940362A (zh) 在慢性ssri方案后使用苯二氮䓬增加对裸盖菇素的敏感性
EA007632B1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
JP5039994B2 (ja) 睡眠障害の治療のためのミルタザピンの使用
EP1613328B1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
US20100317666A1 (en) Composition Comprising An NK-1 Receptor Antagonist And An SSRI For The Treatment Of Tinnitus And Hearing Loss
KR20020086911A (ko) 알츠하이머 질환과 관련된 신경정신적 행동의 치료를 위한갈란타민의 용도
CA2326105A1 (en) New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
CA2558708A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
KR20220020832A (ko) 단백질 감염에 사용하기 위한 3원 약학 조성물

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU